Tonix Pharmaceuticals Files 8-K

Ticker: TNXP · Form: 8-K · Filed: Sep 29, 2025 · CIK: 1430306

Sentiment: neutral

Topics: corporate-filing, 8-K

TL;DR

TONIX files 8-K, check for updates.

AI Summary

Tonix Pharmaceuticals Holding Corp. filed an 8-K on September 29, 2025, reporting on other events and financial statements. The company, incorporated in Nevada, has its principal executive offices in Chatham, New Jersey. This filing follows a name change from Tamandare Explorations Inc. on March 20, 2008.

Why It Matters

This 8-K filing provides an update on Tonix Pharmaceuticals' corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain significant new risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Tonix Pharmaceuticals?

The primary purpose is to report on 'Other Events' and 'Financial Statements and Exhibits' as of September 29, 2025.

When was Tonix Pharmaceuticals Holding Corp. incorporated?

Tonix Pharmaceuticals Holding Corp. was incorporated in Nevada.

What is the address of Tonix Pharmaceuticals' principal executive offices?

The principal executive offices are located at 26 Main Street, Suite 101, Chatham, New Jersey, 07928.

Has Tonix Pharmaceuticals Holding Corp. operated under a different name previously?

Yes, the company was formerly known as Tamandare Explorations Inc.

On what date did the company change its name from Tamandare Explorations Inc.?

The date of the name change was March 20, 2008.

Filing Stats: 918 words · 4 min read · ~3 pages · Grade level 12.8 · Accepted 2025-09-29 08:24:51

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On September 29, 2025, Tonix Pharmaceuticals Holding Corp. (the "Company") announced plans to progress its TNX-2900 product candidate program for the treatment of Prader-Willi syndrome ("PWS") into a Phase 2 clinical trial. A copy of the press release which discusses this matter is furnished hereto as Exhibit 99.01, and incorporated herein by reference. The Company updated its TNX-2900 product candidate presentation, which it intends to place on its website and which may contain nonpublic information. A copy of the presentation is filed as Exhibit 99.02 hereto and incorporated herein by reference. The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.01 and 99.02 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01. Other Events

Item 8.01. Other Events. On September 29, 2025, the Company announced plans to conduct a Phase 2 randomized, double-blind, placebo-controlled, parallel-design study to evaluate the safety, tolerability, and efficacy of TNX-2900 in male and female participants with PWS, ages 8 to 17.5 years, with an anticipated start date in 2026. Eligible participants will be randomized to receive 12-weeks of treatment with TNX-2900 at one of three dose levels, or placebo, in a 1:1:1:1 ratio. The primary efficacy endpoint will be the change from baseline in the validated Hyperphagia Questionnaire for Clinical Trials. Secondary objectives will include assessments of behavior, caregiver burden, quality of life measures, and safety and tolerability outcomes. Forward- Looking Statements This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibit No. Description. 99.01 Press Release of the Company, September 29, 2025 99.02 TNX-2900 Product Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. TONIX PHARMACEUTICALS HOLDING CORP. Date: September 29, 2025 By: /s/ Bradley Saenger Bradley Saenger Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing